Education
About Us
Working with TipRanks
Follow Us
Korro Bio (KRRO)
NASDAQ:KRRO
KRRO Stock Chart & Stats
$5.70
-$1.03(-2.68%)
At close: 4:00 PM EST
$5.70
-$1.03(-2.68%)
Day’s Range― - ―
52-Week Range$5.42 - $56.04
Previous CloseN/A
Volume28.02K
Average Volume (3M)734.66K
Market Cap
$59.14M
Enterprise Value$400.95M
Total Cash (Recent Filing)$93.48M
Total Debt (Recent Filing)$44.67M
Price to Earnings (P/E)―
Beta2.66
Next Earnings
Mar 31, 2026EPS Estimate
-2.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.92
Shares Outstanding9,417,295
10 Day Avg. Volume1,808,258
30 Day Avg. Volume734,659
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)2.12
Price to Sales (P/S)149.54
P/FCF Ratio-4.36
Enterprise Value/Market Cap6.78
Enterprise Value/Revenue54.40
Enterprise Value/Gross Profit54.40
Enterprise Value/Ebitda-4.53
Forecast
1Y Price Target
$56.60Price Target Upside892.98% Upside
Rating ConsensusHold
Number of Analyst Covering9
EPS Forecast (FY)-10.18
Revenue Forecast (FY)$5.04M
Bulls Say, Bears Say
Bulls Say
Clinical TrialsMore than 80% of planned healthy volunteers have been dosed in the KRRO-110 trial with no serious adverse events or dose-limiting toxicities observed.
Development PipelineKorro Bio is moving on with GalNAc delivery for its next development candidates to drive toward a positive proof-of-concept readout.
Market PositionRNA editing holds significant potential based on preclinical data and Korro is one of the leaders in the field.
Bears Say
Clinical SetbacksKorro announced KRRO-110 did not reach target levels of functional AAT following a single administration in AATD patients.
Strategic ChallengesKorro is abandoning the current KRRO-110 formulation and pivoting to a GalNAc-conjugated AATD construct, with a new candidate not expected until 1H26—placing the program clearly behind competitors.
Workforce And Financial ChangesAlongside the scientific setback, Korro announced a 34% workforce reduction and extended its cash runway to 2H27 as it reprioritizes resources toward KRRO-121 for hyperammonemia.
Korro Bio News
KRRO FAQ
What was Korro Bio’s price range in the past 12 months?
Korro Bio lowest stock price was $5.42 and its highest was $56.04 in the past 12 months.
What is Korro Bio’s market cap?
Korro Bio’s market cap is $59.14M.
When is Korro Bio’s upcoming earnings report date?
Korro Bio’s upcoming earnings report date is Mar 31, 2026 which is in 119 days.
How were Korro Bio’s earnings last quarter?
Korro Bio released its earnings results on Nov 12, 2025. The company reported -$1.92 earnings per share for the quarter, beating the consensus estimate of -$2.594 by $0.674.
Is Korro Bio overvalued?
According to Wall Street analysts Korro Bio’s price is currently Undervalued.
Does Korro Bio pay dividends?
Korro Bio does not currently pay dividends.
What is Korro Bio’s EPS estimate?
Korro Bio’s EPS estimate is -2.03.
How many shares outstanding does Korro Bio have?
Korro Bio has 9,417,295 shares outstanding.
What happened to Korro Bio’s price movement after its last earnings report?
Korro Bio reported an EPS of -$1.92 in its last earnings report, beating expectations of -$2.594. Following the earnings report the stock price went down -79.313%.
Which hedge fund is a major shareholder of Korro Bio?
Currently, no hedge funds are holding shares in KRRO
Korro Bio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$56.60 (892.98% Upside)
$56.60 (892.98% Upside)
Hedge Fund Trend
Increased
By 91.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 9.7%
Last 30 Days ▲ 9.7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-88.72%
12-Months-Change
Fundamentals
Return on Equity
-63.46%
Trailing 12-Months
Asset Growth
-33.67%
Trailing 12-Months
Company Description
Korro Bio
Korro Bio, Inc. is a biotechnology company focused on the development of RNA editing technologies to treat a wide array of genetic diseases. The company operates in the biopharmaceutical sector, leveraging its proprietary platform to create transformative therapies that can precisely edit RNA to correct mutations at the RNA level. Korro Bio's core products include its pipeline of RNA editing therapies aimed at addressing unmet medical needs across multiple therapeutic areas.
KRRO Stock 12 Month Forecast
Average Price Target
$56.60
▲(892.98% Upside)
Technical Analysis
Assembly Biosciences
―
Annexon Biosciences
―
4D Molecular Therapeutics
―
Design Therapeutics
―
Aura Biosciences Inc
―